SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bensinger WI. Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia. 2009; 23: 442-448.
  • 2
    Gahrton G, Björkstrand B. Allogeneic transplantation in multiple myeloma. Haematologica. 2008; 93: 1295-1300.
  • 3
    Harousseau JL. The allogeneic dilemma. Bone Marrow Transplant. 2007; 40: 1123-1128.
  • 4
    Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003; 349: 2495-2502.
  • 5
    Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006; 135: 158-164.
  • 6
    Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006; 354: 1021-1030.
  • 7
    Barlogie B, Attal M, Crowley J, Harousseau J. Long-term follow-up of autotransplant (AT)- supported high-dose melphalan (hdm) for multiple myeloma (MM):update of the Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials [abstract]. J Clin Oncol. 2009; 27( suppl 1): 15s. Abstract 8519.
  • 8
    Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006; 24: 929-936.
  • 9
    Björkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996; 88: 4711-4718.
  • 10
    Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996; 88: 2787-2793.
  • 11
    Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001; 113: 209-216.
  • 12
    Kuruvilla J, Shepherd JD, Sutherland HJ, et al. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2007; 13: 925-931.
  • 13
    Khaled Y, Mellacheruvu S, Reddy P, Peres E, Mineishi S. Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect. Bone Marrow Transplant. 2009; 44: 325-326.
  • 14
    Kroger N, Perez-Simon JA, Myint H, et al. Relapse to prior autograft and chronic GVHD are the strongest prognostic factors for outcome of melphalan/fludarabine based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2004; 10: 698-708.
  • 15
    Crawley C, Lalancette M, Szydlo R, et al, for the Chronic Leukaemia Working Party of the EBMT. Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood. 2005; 105: 4532-4539.
  • 16
    Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007; 109: 3588-3594.
  • 17
    Rotta M, Storer BE, Sahebi F, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood. 2009; 113: 3383-3391.
  • 18
    Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007; 356: 1110-1120.
  • 19
    Rosiñol L, Pérez-Simón JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008; 112: 3591-3593.
  • 20
    Moreau P, Garban F, Attal M, et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood. 2008; 112: 3914-3915.
  • 21
    Björkstrand B, Iacobelli S, Hegenbart U, et al. Autologous stem cell transplantation (ASCT) vs ASCT followed by reduced-intensity conditioning (RIC) allogeneic SCT with identical sibling donor in previously untreated multiple myeloma (MM): a prospective controlled trial by the EBMT [abstract]. Bone Marrow Transplant. 2009; 43( suppl 1): S31. Abstract 223.
  • 22
    Stewart AK. Reduced-intensity allogeneic transplantation for myeloma: reality bites. Blood. 2009; 113: 3135-3136.
  • 23
    Madan S, Kumar S, Lacy MQ, et al. Natural history of multiple myeloma (MM) relapsing after autologous stem cell transplantation (ASCT). J Clin Oncol. 2009; 27( suppl 1):Page. Abstract 19513.
  • 24
    de Lavallade H, El-Cheikh J, Faucher C, et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant. 2008; 41: 953-960.
  • 25
    Gerull S, Goerner M, Benner A, et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant. 2005; 36: 963-969.
  • 26
    Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998; 102: 1115-1123.
  • 27
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assos. 1958; 53: 457-481.
  • 28
    Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18: 695-706.
  • 29
    Champlin R, Khouri I, Shimoni A, et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000; 111: 18-29.
  • 30
    Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2006; 20: 322-328.
  • 31
    Shimoni A, Hardan I, Shem-Tov N, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia. 2007; 21: 2109-2116.
  • 32
    Gahrton G, Iacobelli S, Apperley J, et al. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant. 2005; 35: 609-617.
  • 33
    Kroger N, Schilling G, Einsele H, et al. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization as prognostic factor following allogeneic dose-reduced stem cell transplantation in patients with multiple myeloma. Blood. 2004; 104; 4056-4061.
  • 34
    Schilling G, Hansen T, Shimoni A, et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2008; 22: 1250-1255.
  • 35
    Lahuerta JJ, Mateos MV, Martínez-López J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008; 26: 5775-5782.
  • 36
    Corradini P, Cavo M, Lokhorst H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003; 102: 1927-1929.
  • 37
    Ayuk F, Shimoni A, Nagler A, et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia. 2004; 18: 659-662.
  • 38
    Kroger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood. 2004; 104: 3361-3363.
  • 39
    El-Cheikh J, Michallet M, Nagler A, et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica. 2008; 93: 455-458.
  • 40
    Kroger N, Badbaran A, Lioznov M, et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol. 2009; 37: 791-798.